Taken together, in two different preclinical models of myeloid malignancies (APL and HR-MDS) the survival advantage induced by the pVAX14 vaccine was concomitant with increases in IFNγ producing cells, memT, leukemic precursor-specific CD3+ cells and MyD88 expression. Here, IFNG is linked to acute promyelocytic leukemia.